Genenta Science S.p.A. SEC filings GNTA
Genenta Science S.p.A. has 119 filings in SEC EDGAR's recent list, going back to Mar 1, 2021. Its latest annual report, Form 20-F, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026.
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | Apr 1, 2026 | Dec 31, 2025 |
| 20-F | Annual report (foreign issuer) | Mar 28, 2025 | Dec 31, 2024 |
| 20-F/A | Amended annual report (foreign issuer) | Apr 1, 2024 | Dec 31, 2023 |
| 20-F | Annual report (foreign issuer) | Mar 29, 2024 | Dec 31, 2023 |
| 20-F | Annual report (foreign issuer) | Apr 21, 2023 | Dec 31, 2022 |
| 20-F | Annual report (foreign issuer) | May 2, 2022 | Dec 31, 2021 |
Showing 6 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- GNTA (Nasdaq)
- Incorporated in
- Italy
- Headquarters
- Milan, Italy
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1838716
- Former names
- Genenta Science S.r.l. (until May 19, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.